The DFS noted among the patients treated with icotinib (median DFS, 61.8 months for the 12-month group and 63.2 months for the 6-month group) in the ICTAN trial was notably longer than that reported in the EVIDENCE trial (median DFS, 47.0 months).18 The results of this study also revealed an OS benefit of adjuvant icotinib in resected EGFR-mutated stage II–IIIA NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.